3945-18-4

Basic information

• Product Name: 3,4-DI-O-ACETYL-L-ARABINAL
• Synonyms: 3,4-DI-O-ACETYL-L-ARABINAL;3,4-Di-O-acetyl-L-arabinal,97%
• CAS NO: 3945-18-4
• Molecular Formula: C₉H₁₂O₅
• Molecular Weight: 200.19
• Mol File: 3945-18-4.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 266.2 °C at 760 mmHg
• Flash Point: 112.8 °C
• Appearance: Clear colorless to yellow/Oil
• Density: 1.2 g/cm³
• Vapor Pressure: 0.00878mmHg at 25°C
• Refractive Index: 1.458-1.46
• CAS DataBase Reference: 3,4-DI-O-ACETYL-L-ARABINAL(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DI-O-ACETYL-L-ARABINAL(3945-18-4)
• EPA Substance Registry System: 3,4-DI-O-ACETYL-L-ARABINAL(3945-18-4)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 3945-18-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H12O5/c1-6(10)13-8-3-4-12-5-9(8)14-7(2)11/h3-4,8-9H,5H2,1-2H3/t8-,9+/m1/s1

Upstream product

• 3068-29-9 2,3,4-tri-O-acetyl-β-D-arabinosyl bromide 
• 108-24-7 acetic anhydride 
• 100897-60-7 2,3,4-Tri-O-acetyl-α-D-arabino-pyranosyl chloride 
• 50730-32-0 2,3,5-tri-O-acetyl-D-ribopyranosyl bromide 
• 39524-37-3 (2R,3S,4R,5R)-2-bromotetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 107-13-1 acrylonitrile 
• 4258-01-9 1,3,4-tri-O-acetyl-2-deoxy-β-D-erythro-pentopyranose 
• 39524-39-5 2,3,4-tri-O-acetyl-α-D-ribopyranosyl bromide 
• 64-19-7 acetic acid 
• 108646-05-5 (3S,4R,5R)-tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate 
• 28697-53-2 D-arabinopyranose 
• 19186-37-9 1,2,3,4-tetra-O-acetyl-α-D-arabinopyranose 
• 14227-90-8 2,3,4-tri-O-acetyl-α-L-arabinopyranosyl bromide 
• 5328-37-0 L-arabinose 

Downstream Products

• 88377-44-0 α-(4'-O-Acetyl-2',3'-dideoxy-α-D-glycero-pent-2'-enopyranosyl)acetophenone 
• 72946-54-4 1-(5-acetoxy-5,6-dihydro-2H-pyran-2-yl)-4-benzoylamino-1H-pyrimidin-2-one 
• 81666-71-9 4-Amino-1-((2R,5R)-5-hydroxy-5,6-dihydro-2H-pyran-2-yl)-1H-pyrimidin-2-one 
• 123-76-2 levulinic acid 
• 23914-43-4 2,2',4,4',6,6'-Hexachlor-azobenzen 
• 864277-16-7 Acetic acid (3R,6R)-6-(2-benzyloxymethyl-allyl)-3,6-dihydro-2H-pyran-3-yl ester 

Relevant articles and documents

Diastereoselective Synthesis of Thioglycosides via Pd-Catalyzed Allylic Rearrangement

Stereoselective glycosylation is challenging in carbohydrate chemistry. Herein, stereoselective thioglycosylation of glycals via palladium-catalyzed allylic rearrangement yields various substituents on α-isomer thioglycosides. Two comprehensive series of aryl and benzyl thioglycosides were obtained via a combination of thiosulfates with glycals derived from glucose, arabinose, galactose, and rhamnose. Furthermore, diosgenyl α-l-rhamnoside and isoquercitrin achieved selectivity via stereospecific [2,3]-sigma rearrangements of α-sulfoxide-rhamnoside and α-sulfoxide-glucoside, respectively.

Non-naturally Occurring Regio Isomer of Lysophosphatidylserine Exhibits Potent Agonistic Activity toward G Protein-Coupled Receptors

Lysophosphatidylserine (LysoPS), an endogenous ligand of G protein-coupled receptors, consists of l-serine, glycerol, and fatty acid moieties connected by phosphodiester and ester linkages, respectively. An ester linkage of phosphatidylserine can be hydrolyzed at the 1-position or at the 2-position to give 2-acyl lysophospholipid or 1-acyl lysophospholipid, respectively. 2-Acyl lysophospholipid is in nonenzymatic equilibrium with 1-acyl lysophospholipid in vivo. On the other hand, 3-acyl lysophospholipid is not found, at least in mammals, raising the question of whether the reason for this might be that the 3-acyl isomer lacks the biological activities of the other isomers. Here, to test this idea, we designed and synthesized a series of new 3-acyl lysophospholipids. Structure-activity relationship studies of more than 100 "glycol surrogate"derivatives led to the identification of potent and selective agonists for LysoPS receptors GPR34 and P2Y10. Thus, the non-natural 3-acyl compounds are indeed active and appear to be biologically orthogonal with respect to the physiologically relevant 1-and 2-acyl lysophospholipids.

THERAPEUTIC COMPOUNDS

The invention provides compounds of formula (I): and salts thereof, wherein R1, R2, R3, B, X, Y, and Z have any of the values defined herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for preparing compounds of formula (I) and salts thereof, intermediates useful for preparing compounds of formula (I) and salts thereof, and therapeutic methods for treating cancer using a compound of formula (I) or a pharmaceutically acceptable salt thereof.